Menu
Recruiting NCT06175715

General Versus Regional Anesthesia for Carotid Endarterectomy at Acute Ischemic Stroke Trial

No phase Interventional Acute Ischemic Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: carotid endarterectomy.
Who it may be relevant to
Registry conditions: Acute Ischemic Stroke. Basic parameters: 40 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Russia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Study is Planned to Evaluate the Effectiveness and Safety of Two Types of Anesthesia (Regional and General) for Carotid Endarterectomy in 100 Patients With Acute Stage of Stroke: 50 Patients Will be Operated Under Regional Anesthesia and the Remaining 50 Patients Under General Anesthesia.

Overview

The study is planned to evaluate the effectiveness and safety of two types of anesthesia (regional and general) for carotid endarterectomy in 100 patients with acute stage of stroke: 50 patients will be operated under regional anesthesia and the remaining 50 patients under general anesthesia. Patient inclusion criteria: 1. Ischemic stroke in the middle cerebral artery territory 2. Ipsilateral stenosis of the internal carotid artery more than 50% 3. Neurological deficit at the time of surgical treatment: the modified Rankin scale (mRs) score of 0-4 and the US National Institutes of Health (NIHSS) stroke scale score no more than 12 4. The size of the ischemia focus: no more than 1/3 in the territory of the middle cerebral artery brain supply 5. Terms of operation: from 1 to 28 days from the moment of ischemic stroke The primary intra-hospital and/or 30-day study endpoints: 1. Perioperative ipsilateral ischemic stroke. 2. Any stroke: contralateral ischemic or any hemorrhagic stroke. 3. Myocardial infarction. 4. Hemorrhagic complications that required surgical revision of the operating wound or transfusion of blood components. 5. Surgical site infection 6. Death 7. Main adverse cardiovascular events (stroke + myocardial infarction + death).

Interventions

  • Procedure carotid endarterectomy
    carotid endarterectomy under local or general anethesia

Primary outcome measures

  • Rate of perioperative ipsilateral ischemic stroke (%) [Time frame: in hospital, 30-day, 1 year]
  • Rate of any stroke (%) [Time frame: in hospital, 30-day, 1 year]
  • Rate of Myocardial infarction (%) [Time frame: in hospital, 30-day, 1 year]
  • Rate of Hemorrhagic complications (%) [Time frame: in hospital, 30-day, 1 year]
  • Rate of Surgical site infection (%) [Time frame: in hospital, 30-day, 1 year]
  • Rate of Death (%) [Time frame: in hospital, 30-day, 1 year]
  • Rate of main adverse cardiovascular events (%) [Time frame: in hospital, 30-day, 1 year]

Eligibility criteria

Inclusion criteria

  • 1\. Ischemic stroke in the middle cerebral artery territory 2. Ipsilateral stenosis of the internal carotid artery more than 50% 3. Neurological deficit at the time of surgical treatment: the modified Rankin scale (mRs) score of 0-4 and the US National Institutes of Health (NIHSS) stroke scale score no more than 12 4. The size of the ischemia focus: no more than 1/3 in the territory of the middle cerebral artery brain supply 5. Terms of operation: from 1 to 28 days from the moment of ischemic stroke

Exclusion criteria

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Sequential
Masking
Single blind
Primary purpose
Treatment

Study locations

Russia · 1 center
  • Pryamikov Aleksandr — Moscow

Identifiers

NCT: NCT06175715 · 1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗